Information Provided By:
Fly News Breaks for July 15, 2019
CYTK, AMGN
Jul 15, 2019 | 12:51 EDT
Piper Jaffray analyst Edward Tenthoff reiterated an Overweight rating and $14 price target on Cytokinetics (CYTK) after Amgen (AMGN) completed enrollment of more than 8,200 Heart Failure patients in its Phase III GALACTIC-HF trial of omecamtiv mecarbil. The analyst anticipates an interim GALACTIC-HF efficacy analysis in 2020, with final data likely in 2021.